Bio-Bridge Science granted Japanese patent covering use of papilloma pseudovirus

Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Japanese Patent Office has granted claims in a patent application, and issued a Patent Number 4472724, regarding the use of the papilloma pseudovirus. Bio-Bridge Science has previously been granted patents relating to the papilloma pseudovirus technology and preparation in the United States and China. Loyola University Chicago owns the patent and has exclusively licensed the technology to Bio-Bridge Science, Inc.

“We are pleased to receive the patent from the Japanese Patent Office”

"We are pleased to receive the patent from the Japanese Patent Office," said Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science. "The addition of this new patent strengthens our intellectual property portfolio focused on our papilloma pseudovirus technology exclusively licensed from Loyola University Chicago."